|
Patient Info
Information for Patients:
Please refer to the patient package insert.
Patients should be advised: • to read the patient package insert for PLETAL carefully before starting therapy and to reread it each time therapy is renewed in case the information has changed. Text Continues Below
• to take PLETAL at least one-half hour before or two hours after food. • that the beneficial effects of PLETAL on the symptoms of intermittent claudication may not be immediate. Although the patient may experience benefit in 2 to 4 weeks after initiation of therapy, treatment for up to 12 weeks may be required before a beneficial effect is experienced. • about the uncertainty concerning cardiovascular risk in long-term use or in patients with severe underlying heart disease, as described under PRECAUTIONS. Hepatic Impairment: Patients with moderate or severe hepatic impairment have not been studied in clinical trials. Special caution should be advised when PLETAL is used in patients with severe hepatic impairment.
Renal Impairment:
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95-98%). Special caution should be advised when PLETAL is used in patients with severe renal impairment: creatinine clearance < 25 ml/min.
|
.gif)
